Pharos collaborated with Coalition Plus to support PKNI, the drug user’s network of Indonesia, in developing a preliminary investment case for scale-up. To date, Indonesia has not yet developed a national hepatitis strategy. We modeled several elimination scenarios, using a model developed by the University of Bristol to estimate the costs and cost-effectiveness of each scenario in order to inform the government’s decision-making process as it seeks to develop a strategy and future targets. PKNI used this work to advise the government in the development of its future policy and to advocate for increased investment in hepatitis C nationally.

Below is the abstract describing the final modeling results. Read the full paper here:

Team members: Lindsey Hiebert, Adam Trickey, Peter Vickerman, Carl Schutte, Rob Hecht

LEARN MORE about Pharos Global Health Advisors response to the COVID-19 pandemic.